Drug Profile
Bictegravir - Gilead Sciences
Alternative Names: Bictegravir controlled release - Gilead Sciences; GS 9883Latest Information Update: 08 Mar 2024
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antiretrovirals; Oxazepines; Pyrazines; Pyridones; Small molecules
- Mechanism of Action HIV integrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III HIV-1 infections
- Discontinued HIV infections
Most Recent Events
- 05 Mar 2024 Efficacy and adverse event data from the phase II/III ARTISTRY-1 trial in HIV-1 infections released by Gilead Sciences
- 07 Nov 2022 Discontinued - Phase-I for HIV infections treatment in USA (PO) (Gilead Sciences pipeline, November 2022)
- 07 Nov 2022 Discontinued - Phase-II/III for HIV-1 infections (Combination therapy, Treatment-experienced) in USA (PO) (Gilead Sciences pipeline, November 2022)